Nina S McCarthy1, Ciara Vangjeli2, Praveen Surendran3, Achim Treumann4, Cathy Rooney2, Emily Ho2, Peter Sever5, Simon Thom5, Alun D Hughes5, Patricia B Munroe6, Philip Howard6, Toby Johnson7, Mark Caulfield6, Denis C Shields8, Eoin O'Brien8, Desmond J Fitzgerald8, Alice V Stanton2. 1. Molecular and Cellular Therapeutics, Royal College of Surgeons in Ireland, RCSI, Dublin, Ireland; Centre for the Genetic Origins of Health and Disease, University of Western Australia, Perth, Australia. Electronic address: nina.mccarthy@uwa.edu. 2. Molecular and Cellular Therapeutics, Royal College of Surgeons in Ireland, RCSI, Dublin, Ireland. 3. Molecular and Cellular Therapeutics, Royal College of Surgeons in Ireland, RCSI, Dublin, Ireland; School of Medicine, UCD Conway Institute, University College Dublin, Dublin, Ireland. 4. Newcastle University Protein and Proteome Analysis (NUPPA), University of Newcastle, Newcastle upon Tyne, UK. 5. International Centre for Circulatory Health, Imperial College London, London, UK. 6. Clinical Pharmacology, William Harvey Research Institute, Barts and the London Medical School, Queen Mary University of London and NIHR Barts Cardiovascular Biomedical Research Unit, London, UK. 7. Clinical Pharmacology, William Harvey Research Institute, Barts and the London Medical School, Queen Mary University of London and NIHR Barts Cardiovascular Biomedical Research Unit, London, UK; GlaxoSmithKline, Gunnels Wood Road, Stevenage SG1 2NY, UK. 8. School of Medicine, UCD Conway Institute, University College Dublin, Dublin, Ireland.
Abstract
BACKGROUND AND AIMS: Elevated urinary 11-dehydro thromboxane B2 (TxB2), a measure of thromboxane A2 formation in vivo, predicts future atherothrombotic events. To further understand this relationship, the genetic determinants of 11-dehydro TxB2 and their associations with cardiovascular morbidity were investigated in this study. METHODS: Genome-wide and targeted genetic association studies of urinary 11-dehydro TxB2 were conducted in 806 Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT) participants. RESULTS: The strongest associations were in PPARGC1B (rs4235745, rs32582, rs10515638) and CNTN4 (rs10510230, rs4684343), these 5 single nucleotide polymorphisms (SNPs) were independently associated with 11-dehydro TxB2 formation. Haplotypes of 11-dehydro TxB2 increasing alleles for both PPARGC1B and CNTN4 were significantly associated with 11-dehydro TxB2, explaining 5.2% and 4.5% of the variation in the whole cohort, and 8.8% and 7.9% in participants not taking aspirin, respectively. In a second ASCOT population (n = 6199), addition of these 5 SNPs significantly improved the covariate-only Cox proportional hazards model for cardiovascular events (chisq = 14.7, p=0.01). Two of the risk alleles associated with increased urinary 11-dehydro TxB2 were individually associated with greater incidences of cardiovascular events - rs10515638 (HR = 1.31, p=0.01) and rs10510230 (HR = 1.25, p=0.007); effect sizes were larger in those not taking aspirin. CONCLUSIONS: PPARGC1B and CNTN4 genotypes are associated with elevated thromboxane A2 formation and with an excess of cardiovascular events. Aspirin appears to blunt these associations. If specific protection of PPARGC1B and CNTN4 variant carriers by aspirin is confirmed by additional studies, PPARGC1B and CNTN4 genotyping could potentially assist in clinical decision making regarding the use of aspirin in primary prevention.
BACKGROUND AND AIMS: Elevated urinary 11-dehydro thromboxane B2 (TxB2), a measure of thromboxane A2 formation in vivo, predicts future atherothrombotic events. To further understand this relationship, the genetic determinants of 11-dehydro TxB2 and their associations with cardiovascular morbidity were investigated in this study. METHODS: Genome-wide and targeted genetic association studies of urinary 11-dehydro TxB2 were conducted in 806 Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT) participants. RESULTS: The strongest associations were in PPARGC1B (rs4235745, rs32582, rs10515638) and CNTN4 (rs10510230, rs4684343), these 5 single nucleotide polymorphisms (SNPs) were independently associated with 11-dehydro TxB2 formation. Haplotypes of 11-dehydro TxB2 increasing alleles for both PPARGC1B and CNTN4 were significantly associated with 11-dehydro TxB2, explaining 5.2% and 4.5% of the variation in the whole cohort, and 8.8% and 7.9% in participants not taking aspirin, respectively. In a second ASCOT population (n = 6199), addition of these 5 SNPs significantly improved the covariate-only Cox proportional hazards model for cardiovascular events (chisq = 14.7, p=0.01). Two of the risk alleles associated with increased urinary 11-dehydro TxB2 were individually associated with greater incidences of cardiovascular events - rs10515638 (HR = 1.31, p=0.01) and rs10510230 (HR = 1.25, p=0.007); effect sizes were larger in those not taking aspirin. CONCLUSIONS: PPARGC1B and CNTN4 genotypes are associated with elevated thromboxane A2 formation and with an excess of cardiovascular events. Aspirin appears to blunt these associations. If specific protection of PPARGC1B and CNTN4 variant carriers by aspirin is confirmed by additional studies, PPARGC1B and CNTN4 genotyping could potentially assist in clinical decision making regarding the use of aspirin in primary prevention.
Authors: K S Park; H D Shin; B L Park; H S Cheong; Y M Cho; H K Lee; J-Y Lee; J-K Lee; H Tae Kim; C-S Park; B G Han; K Kimm; B Oh Journal: Diabet Med Date: 2006-06 Impact factor: 4.359
Authors: Aline Meirhaeghe; Vivion Crowley; Carol Lenaghan; Christopher Lelliott; Kath Green; Abigail Stewart; Kevin Hart; Sven Schinner; Jaswinder K Sethi; Giles Yeo; Martin D Brand; Ron N Cortright; Stephen O'Rahilly; Carl Montague; Antonio J Vidal-Puig Journal: Biochem J Date: 2003-07-01 Impact factor: 3.857
Authors: Maryam Ahmadian; Jae Myoung Suh; Nasun Hah; Christopher Liddle; Annette R Atkins; Michael Downes; Ronald M Evans Journal: Nat Med Date: 2013-05-07 Impact factor: 53.440
Authors: Colin Baigent; Lisa Blackwell; Rory Collins; Jonathan Emberson; Jon Godwin; Richard Peto; Julie Buring; Charles Hennekens; Patricia Kearney; Tom Meade; Carlo Patrono; Maria Carla Roncaglioni; Alberto Zanchetti Journal: Lancet Date: 2009-05-30 Impact factor: 79.321
Authors: Venkata Saroja Voruganti; Jack W Kent; Subrata Debnath; Shelley A Cole; Karin Haack; Harald H H Göring; Melanie A Carless; Joanne E Curran; Matthew P Johnson; Laura Almasy; Thomas D Dyer; Jean W Maccluer; Eric K Moses; Hanna E Abboud; Michael C Mahaney; John Blangero; Anthony G Comuzzie Journal: Front Genet Date: 2013-12-16 Impact factor: 4.599